Aradigm Corporation Release: Two Presentations On Aradigm’s Inhaled Liposomal Ciprofloxacin Programs At The American Thoracic Society 2016 International Conference

HAYWARD, Calif.--(BUSINESS WIRE)--The first presentation is co-authored by an international team of investigators and employees of Aradigm Corporation (NASDAQ:ARDM) (the “Company”); it discusses the details of the design of the ongoing Phase 3 clinical trials ORBIT-3 and ORBIT-4 investigating the safety and efficacy of the Company’s investigational drug product Pulmaquin® in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with Pseudomonas aeruginosa (PA).